Antifungal activity of phenolic compounds identified in flowers from North Eastern Portugal against Candida species

Future Microbiology

Volumn 9, Issue 2, 2014, Pages 139-146

  Alves, Carlos Tiago ^a   Ferreira, Isabel Cfr F R ^b   Barros, Lillian ^b   Silva, Sónia ^a   Azeredo, Joana ^a   Henriques, Mariana ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b INSTITUTO POLITÉCNICO DE BRAGANÇA   (Portugal)

Author keywords

Antifungal effect; Biofilms; Candida species; Medicinal flowers; Phenolic compounds

Indexed keywords

CATECHIN; GALLIC ACID; LUTEOLIN; QUERCETIN;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; FLOWER; FUNGAL CELL; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PORTUGAL; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDIASIS; CATECHIN; FLOWERS; GALLIC ACID; LUTEOLIN; MICROBIAL SENSITIVITY TESTS; PHENOLS; PLANT PREPARATIONS; PORTUGAL; QUERCETIN;

EID: 84896842376     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.147     Document Type: Article

References (47)

1. Soll DR. Candida commensalism and virulence: the evolution of phenotypic plasticity. Acta Trop. 81, 101-110 (2002). (Pubitemid 34093800)
2. Calderone RA. Introduction and historical perspectives. In: Candida and Candidiasis. Calderon RA (Ed.). ASM Press, Washington DC, USA, 15-25 (2002).
3. Chandra J, Kuhn D, Mukherjee P et al. Biofilm formation by fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183, 5385-5394 (2001). (Pubitemid 32802612)
4. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 11, 30-36 (2003). (Pubitemid 36084353)
5. Ganguly S, Mitchell AP. Mucosal biofilms of Candida albicans. Curr. Opin. Microbiol. 14(4), 380-385 (2011).
6. Finkel JS, Mitchell AP. Genetic control of Candida albicans biofilm development. Nat. Rev. Microbiol. 9, 109-118 (2011).
7. Fux CA, Costerton JW, Stewart PS et al. Survival strategies of infectious biofilms. Trends Microbiol. 13, 34-40 (2005). (Pubitemid 40082395)
8. Ramage G, Saville SP. Candida biofilms: an update. Eukaryot. Cell 4(4), 633-638 (2005). (Pubitemid 40600417)
9. Pereira Gonzales F, Maisch T. Photodynamic inactivation for controlling Candida albicans infections. Fungal Biol. 116(1), 1-10 (2012).
10. Harriott MM, Lilly EA, Rodriguez TE et al. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156, 3635-3644 (2010).
11. Hasan F, Xess I, Wang X et al. Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect. 11, 753-761 (2009).
12. Martins M, Henriques M, Ribeiro AP et al. Oral carriage of patients attending a dental clinic in Braga, Portugal. Rev. Iberoam. Micol. 27, 119-124 (2010).
13. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27, 359-366 (2006).
14. Redding S, Kirkpatrick W, Coco B et al. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J. Clin. Microbiol. 40, 1879-1881 (2002). (Pubitemid 34493182)
15. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr. Drug Targets 7, 495-504 (2006). (Pubitemid 43744840)
16. Gonzalez GM, Eliondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-years (2004 to 2007) surveillance study. J. Clin. Microbiol. 46, 2902-2905 (2008).
17. Negri M. Henriques M, Svidzinski TI et al. Correlation between Etest®, disk diffusion, and microdilution methods for antifungal susceptibility testing of Candida species from infection and colonization. J. Clin. Lab. Anal. 23, 324-330 (2009).
18. Muñoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int. J. Antimicrob. Agents 15, 83-90 (2000). (Pubitemid 30347248)
19. Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit. Care Med. 37, 1624-1633 (2009).
20. Sobel JD. Changing epidemiology of invasive candidiasis in intensive care units - much ado about nothing? Crit. Care Med. 36, 2188-2189 (2008).
21. Dai YC, Yang ZL, Cui BK et al. Species diversity and utilization of medicinal mushrooms and fungi in China (review). Int. J. Med. Mushrooms 11, 287-302 (2009).
22. Saleem M, Nazir M, Ali MS et al. Antimicrobial natural products: an update on future antibiotic drug candidates. Nat. Prod. Rep. 27, 238-54 (2010). • Excellent article for understanding the potential of natural compounds.
23. Palaniappan K, Holley RA. Use of natural antimicrobials to increase antibiotic susceptibility of drug resistant bacteria. Int. J. Food Microbiol. 140(2-3), 164-168 (2010).
24. Barros L, Dueñas M, Carvalho AM et al. Characterization of phenolic compounds in flowers of wild medicinal plants from Northeastern Portugal. Food Chem. Toxicol. 50, 1576-1582 (2012). •• Excellent article for understanding the full characterization of phenolic compounds.
25. Barros L, Alves CT, Dueñas M et al. Characterization of phenolic compounds in wild medicinal flowers from Portugal by HPLC-DAD-ESI/MS and evaluation of antifungal properties. Indust. Crops Prod. 44, 104-110 (2013). •• Excellent article for understanding the full characterization of phenolic compounds.
26. Barros L, Dueñas M, Alves CT et al. Antifungal activity and detailed chemical characterization of Cistus ladanifer phenolic extracts. Indust. Crops Prod. 41, 41-45 (2013). •• Excellent article for understanding the full characterization of phenolic compounds.
27. Pfaller MA, Chaturvedi V, Espinel-Ingroff A et al. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - second edition. National Committee for Clinical Laboratory Standards, PA, USA, 22(15) (2002). • Excellent article for understanding the MIC technique.
28. Naeini A, Khosravi AR, Chitsaz M et al. Anti-Candida albicans activity of some Iranian plants used in traditional medicine. J. Mycol. Med. 19, 168-172 (2009).
29. Ross J, Kasum C. Dietary flavonoids: bioavailability, metabolic effects, and safety. Ann. Rev. Nutr. 22(1), 19-34 (2002). (Pubitemid 35221452)
30. Whiting D. Natural phenolic compounds 1900-2000: a bird's eye view of a century's chemistry. Nat. Prod. Rep. 18(6), 583-606 (2001). (Pubitemid 34010013)
31. Haghighi F, Roudbar Mohammadi SH, Farhadi Z. The effect of catechin on fungal biofilm formation of standard susceptible and resistant strains of Candida albicans. Armaghan Danesh 16(4 (64)), 340-332 (2011).
32. Hong LS, Ibrahim D, Kassim J et al. Gallic acid: an anticandidal compound in hydrolysable tannin extracted from the barks of Rhizophora apiculata Blume. J. Appl. Pharm. Sci. 01(06), 75-79 (2011).
33. Lv PC, Li HQ, Xue JY et al. Synthesis and biological evaluation of novel luteolin derivatives as antibacterial agents. Eur. J. Med. Chem. 44, 908-914 (2009).
34. Arima H, Ashida H, Danno G. Rutin-enhanced antibacterial activities of flavonoids against Bacillus cereus and Salmonella enteritidis. Biosci. Biotechnol. Biochem. 66, 1009-1014 (2002). (Pubitemid 39251295)
35. Ozdemir Z. Growth inhibition of Clavibacter michiganesis subsp. michiganensis and Pseudomonas syrigae pv. Tomato by olive mill wastewaters and citric acid. J. Plant Pathol. 91(1), 221-224 (2009).
36. Saravanakumar A, Venkateshwaran K, Vanitha J et al. Evaluation of antibacterial activity, phenol and flavonoid contents of Thespesiapopulnea flower extracts. Pak. J. Pharm. Sci. 22(3), 282-286 (2009).
37. Sudjana AN, D'Orazio C, Ryan V et al. Antimicrobial activity of commercial Olea europaea (olive) leaf extract. Int. J. Antimicrob. Agents 33(5), 461-463 (2009).
38. Kim KJ, Woo SS, Bo KS et al. Activity and mode of action of silver nano-particles on Candida albicans. Biometals 22, 235-242 (2009).
39. Endo EH, Cortez DA, Ueda-Nakamura T et al. Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans. Res. Microbiol. 61(7), 534-540 (2010).
40. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12(4), 501-517 (1999). (Pubitemid 29484744)
41. Butler G, Rasmussen MD, Lin MF et al. Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature 459, 657-662 (2009).
42. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167-193 (2002). (Pubitemid 34303762)
43. Baillie GS, Douglas L. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol. 310, 644-656 (1999). (Pubitemid 29504312)
44. Costerton JW, Stewart P, Greenberg E. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318-1322 (1999). (Pubitemid 29289651)
45. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39, 2128-2131 (1995).
46. Wang C, Cheng H, Guan Y et al. [In vitro activity of gallic acid against Candida albicans biofilms]. Zhongguo Zhong Yao Za Zhi 34(9), 1137-1140 (2009).
47. Silva S, Henriques M, Martins A et al. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med. Mycol. 46, 1-9 (2009). • Excellent article for understanding the characterization of biofilms of non-Candida albicans Candida species.